Skip to content
Credit reportVerdict and grounds
Made on 21-11-2026 at 07:37
Reference CK-0895359290-20261121

SD PHARMA

ActivePrivate limited company0895.359.290Wetzerstraat 6, 3570 Alken
Activities of holding companies (NACE 64210) · founded in 2008 · one director · accounts in the micro format

Sources: the KBO register on 21-11-2026; the National Bank, 2025 annual accounts filed on 31-07-2026; the Belgian Official Gazette, latest deed of 06-12-2023.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 15,072 micro companies in the financial services sector (NACE 64) is 0.1%.
Gross margin
€127,292
▼ 1.9% against 2024
Net result
€89,819
▲ 0.9% against 2024
Equity
€1.0m
▲ 9.4% against 2024
Cash
€22,904
▼ 38.7% against 2024

Grounds

the facts the verdict rests on, each with its source
  1. SD PHARMA made a profit in every financial year since 2008.Annual accounts 2008 to 2025 page 2
  2. Equity stands at €1.0m, or 86.6% of the balance sheet total of €1.2m. The solvency of 86.6% is higher than at 85% of the 10,288 companies filing micro accounts in financial services (NACE 64) in 2025.Annual accounts 2025 page 2
  3. The 2025 accounts came in on the last day of the term; the 2024 accounts 12 days late.National Bank, filing of 31-07-2026 page 5

Representation

The sole director, , represents SD PHARMA alone.

Articles of association, Belgian Official Gazette of 06-12-2023, deed 23447433

Ownership

The accounts in the micro format list no shareholders. is a shareholder. According to the deed of 03-03-2014, holds all the shares.

Deed of 03-03-2014, deed 14054272

SD PHARMA · 0895.359.290 · credit report of 21-11-2026Page 1 of 6
SD PHARMA0895.359.290 · report of 21-11-2026

Financial situation

Annual accounts 2021 to 2025, as filed with the National Bank

Gross margin and net resultin €m

20210.120220.120230.120240.120250.120210.120220.0920230.0920240.0920250.09
gross marginnet result

Equity and debtsin €m

202120222023202420251.00.2
equitydebts

Cashin €m

20210.0020220.0120230.0320240.0420250.02
on the balance sheet date
Financial year20212022202320242025Trend
Results
Gross margin€143,713€145,134€131,850€129,775€127,292
Operating result€140,811€142,829€129,490€127,164€124,817
Net result€95,548€90,720€90,068€89,023€89,819
Balance sheet at the closing date
Equity€686,668€777,388€867,456€956,479€1.0m
Debts€398,633€311,740€245,287€199,105€161,321
Debts due after more than one year€230,819€167,834€131,386€94,459€57,045
Debts due within one year€167,814€143,906€112,701€104,647€104,276
Cash€770€5,877€26,089€37,364€22,904
Balance sheet total€1.1m€1.1m€1.1m€1.2m€1.2m
Ratios
Solvency63.3%71.4%78.0%82.8%86.6%
Liquidity0.130.190.440.681.15

Source: Annual accounts 2025, micro format, filed on 31-07-2026 (2026-00365837); Annual accounts 2024, micro format, filed on 12-08-2025 (2025-00371206); Annual accounts 2021 to 2023, filed from 21-07-2022 to 29-07-2024 (2022-20211714, 2023-00324295, 2024-00294254).

Debts fell by €37,785 in 2025.

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

SD PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from €129,775 to €127,292.

SD PHARMA · 0895.359.290 · credit report of 21-11-2026Page 2 of 6
SD PHARMA0895.359.290 · report of 21-11-2026

Board, signature and ownership

Position on 21-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

The sole director, , represents SD PHARMA alone.

Articles of association, Belgian Official Gazette of 06-12-2023, deed 23447433

Board

one director in office
Director (not named in the articles)appointed by deed of 06-12-2023
term without a fixed enddeed of 06-12-2023

Ownership and group

Shareholders

The accounts in the micro format list no shareholders. is a shareholder. According to the deed of 03-03-2014, holds all the shares.

Deed of 03-03-2014, deed 14054272

Board changes

changes role from manager to director. General meeting of 30-11-2023.

Gazette, deed 23447433
SD PHARMA · 0895.359.290 · credit report of 21-11-2026Page 3 of 6
SD PHARMA0895.359.290 · report of 21-11-2026

Holdings

SD PHARMA has 1 direct subsidiary (own 2025 accounts).

Country Company Equity Result
Belgium 1
BE €383,912 result €16,674

Source: List of holdings in its own 2025 accounts. Every holding stands with its own latest accounts.

SD PHARMA · 0895.359.290 · credit report of 21-11-2026Page 4 of 6
SD PHARMA0895.359.290 · report of 21-11-2026

Events and comparison

The latest events, newest first

Annual accounts 2025 filed. On the deadline day.

NBB filing

Equity above €1m. With a profit in every financial year since 2008, equity grows to €1.0m.

Financial

Annual accounts 2024 filed, 12 days late.

NBB filing

Annual accounts 2023 filed, 2 days before the deadline.

NBB filing

Annual accounts 2022 filed, 10 days late.

NBB filing

Annual accounts 2021 filed, 10 days before the deadline.

NBB filing

Highest result from 2008 to 2025. The net result of €95,548 is the highest of those years.

Financial

Annual accounts 2020 filed, 1 day before the deadline.

NBB filing

Annual accounts 2019 filed, 31 days before the deadline.

NBB filing

Equity above €500,000. With a profit in every financial year since 2008, equity grows to €554,439.

Financial

Annual accounts 2018 filed. On the deadline day.

NBB filing

Annual accounts 2017 filed, 9 days late.

NBB filing

Annual accounts 2016 filed, 25 days before the deadline.

NBB filing

Registered office moved from Sint-Truiden to Alken. The registered office moved from Stapelstraat 20, 3800 Sint-Truiden to Wetzerstraat 6 A, 3570 Alken. General meeting of 01-01-2017.

Gazette, deed 17031315

The return on assets of SD PHARMA, 7.4%, is higher than at 45% of the 10,139 companies filing micro accounts in financial services (NACE 64) in 2025.

Other findings

Peppol

Reachable for e-invoices since 24-11-2025, under 0208:0895359290.

Sanctions lists

SD PHARMA · 0895.359.290 · credit report of 21-11-2026Page 5 of 6
SD PHARMA0895.359.290 · report of 21-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units21-11-2026KBO 0895.359.290
National Bank of BelgiumAnnual accounts 2025, micro format31-07-20262026-00365837
National Bank of BelgiumAnnual accounts 2024, micro format12-08-20252025-00371206
National Bank of BelgiumAnnual accounts 2021 to 202321-07-2022 to 29-07-20242022-20211714, 2023-00324295, 2024-00294254
Belgian Official GazetteArticles of association with the signing rule06-12-2023deed 23447433
Belgian Official GazetteAll shares held by one shareholder03-03-2014deed 14054272
Peppol DirectoryRegistration for e-invoices24-11-20250208:0895359290
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name19-11-2026
CheckedChecked score, bankruptcy probability, credit, comparable companies20-11-2026bankruptcy model of 2 October 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 20-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

The scores and ratios are Checked's own calculations, not a credit decision.

SD PHARMA · 0895.359.290 · credit report of 21-11-2026Page 6 of 6